Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02109770 · ClinicalTrials.gov registry record
Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Cell Free DNA
A clinical trial, sponsored by Natera.
- Completed
- Registry status
- 216
- Enrollment target
NCT02109770 is a clinical trial that has completed, run by Natera. The registered enrollment target is 216 participants.
The verdict
NCT02109770 has completed, sponsored by Natera.
- COMPLETED
- Registry status
- 216 participants
- Enrollment target
Study Summary
The purpose of this study is to collect blood from families with a child who has been diagnosed with a chromosomal disorder including microdeletions in order to further develop a non-invasive prenatal screening test based on fetal DNA isolated from maternal blood.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2012-10 |
| Est. Completion | 2019-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02109770
The ClinicalTrials.gov registry entry for NCT02109770 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Natera, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02109770 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02109770 about?
NCT02109770 is a clinical study titled "Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Cell Free DNA". The purpose of this study is to collect blood from families with a child who has been diagnosed with a chromosomal disorder including microdeletions in order to further develop a non-invasive prenatal screening test based on fetal DNA isolated from maternal blood.
What is the current status of trial NCT02109770?
This trial is currently completed. The enrollment target is 216 participants. The study started on 2012-10. Estimated completion is 2019-08.
Who is sponsoring clinical trial NCT02109770?
This trial is sponsored by Natera, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.